HORMONE REPLACEMENT THERAPY - Medsafe
HORMONE REPLACEMENT THERAPY These new key messages are based on recent research fi ndings on the risks associated with the use of Combined Hormone Replacement ...
Download HORMONE REPLACEMENT THERAPY - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Guidelines for the Diagnosis and Management of ...
gi.org308 PRACTICE GUIDELINES nature publishing group The American Journal of GASTROENTEROLOGY VOLUME 108 | MARCH 2013 www.amjgastro.com see related editorial on page x Gastroesophagal e fler ux disease (GERD) is arguably the most common disease encountered by the gastroenterologist.
Guidance on menopause and the - Faculty of Occupational ...
www.fom.ac.ukGuidance for women For women who find their menopausal symptoms are affecting their wellbeing and their capacity to work: • Find out more about the menopause from available sources
Guide to Understanding ITP - ITP Foundation
www.itpfoundation.org03.06.2011 © 2011 Dr. Paul Imbach – ITP Foundation and ICIS Basel Switzerland 1 Guide to Understanding ITP (Immune thrombocytopenia) Immune thrombocytopenia (ITP)
NORPRESS 1. Product Name 2. Qualitative and Quantitative ...
www.medsafe.govt.nzPage 1 of 10 NEW ZEALAND DATA SHEET NORPRESS . 1. Product Name Norpress, 10 mg & 25 mg, film coated tablet. 2. Qualitative and Quantitative Composition
GUIDELINES FOR MANAGEMENT OF ADVERSE …
www.nzblood.co.nznational 111i01502 guidelines for management of adverse transfusion reactions page 2 of 8 reaction/cause signs & symptoms prevention management
EPOS - Southern States Rhinology
www.southernstatesrhinology.org6 Acute Rhinosinusitus To evaluate the total severity, the patient is asked to indicate on a VAS the answer to the question: How troublesome are your symptoms of rhinosinusitis?